Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Warrant (NQ: SBFMW )

0.1403 -0.0157 (-10.06%)
Streaming Delayed Price Updated: 3:57 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,134
Open 0.1864
Bid (Size) 0.1400 (14)
Ask (Size) 0.2200 (3)
Prev. Close 0.1560
Today's Range 0.1323 - 0.1864
52wk Range 0.0360 - 0.7662
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sunshine Biopharma Q2 Report Reveals Approximately 1,940% Increase In Cash & Cash Equivalents And 80% Decrease In Net Loss Within 6 Months
Sunshine Biopharma, Inc. (NASDAQ: SBFM) (NASDAQ: SBFMW) announced that it has filed its 2022 second-quarter report with the Securities and Exchange Commission. 
Via Benzinga
Sunshine Biopharma Reveals Potential Intellectual Property Position In Connection With Ongoing mRNA-As-Therapeutics-Agents Research
Photo credit: Patent application by Nick Youngson CC BY-SA 3.0 
Via Benzinga

Performance

YTD
-17.47%
-17.47%
1 Month
+27.55%
+27.55%
3 Month
+100.43%
+100.43%
6 Month
-17.52%
-17.52%
1 Year
-76.64%
-76.64%

More News

Read More
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
Via Benzinga
Sunshine Biopharma Sees Potential Multi-Billion Dollar Global Market Opportunity As Research Findings Reveal Effectiveness Against Multidrug-Resistant Cancer Cells
Via Benzinga
Sunshine Biopharma, Inc. Announces Pricing of $8 Million Private Placement Priced At-the-Market
Via Benzinga
Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)
From Aegis Capital Corp.
Via AccessWire
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.